Discontinued — last reported Q4 '21
Routine clinical testing services — Net revenues
Quest Diagnostics Routine clinical testing services — Net revenues decreased by 25.5% to $901.00M in Q4 2021 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests higher patient volume or improved pricing power in core diagnostic services, while a decrease may indicate competitive pressure or reduced utilization of routine healthcare screenings.
Detailed definition
This metric represents the total net revenue generated from high-volume, standardized diagnostic testing services, such...
Peer comparison
Comparable to core diagnostic testing revenue segments at other major clinical laboratory companies like LabCorp, where routine testing serves as the primary revenue base.
dgx_segment_routine_clinical_testing_services_net_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | |
|---|---|---|---|
| Value | $1.15B | $1.21B | $901.00M |
| QoQ Change | — | +5.2% | -25.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Quest Diagnostics's routine clinical testing services — net revenues?
- Quest Diagnostics (DGX) reported routine clinical testing services — net revenues of $901.00M in Q4 2021.
- What does routine clinical testing services — net revenues mean?
- The total revenue earned from standard, high-volume diagnostic laboratory tests.